LDL Cholesterol Test Price in Badambadi Road

Test Description

Low-Density Lipoprotein Cholesterol (LDL-C) is the primary atherogenic lipoprotein, responsible for transporting cholesterol from the liver to peripheral tissues and depositing it in arterial walls — initiating and propagating the atherosclerotic process. LDL-C is the primary therapeutic target in cardiovascular risk reduction. LDL-C can be calculated (Friedewald equation: LDL-C = Total Cholesterol − HDL-C − [Triglycerides ÷ 5] in mg/dL; invalid when TG >400 mg/dL) or directly measured by homogeneous enzymatic assays. Normal/Optimal LDL-C: <100 mg/dL (very high-risk patients: <70 mg/dL; extreme-risk patients: <55 mg/dL per ESC/EAS 2019 guidelines). ACC/AHA 2018 Cardiovascular Risk Categories: Very High Risk (ASCVD event <70 mg/dL); High Risk (<100 mg/dL); Moderate Risk (<130 mg/dL); Low Risk (<160 mg/dL). Each 1 mmol/L (38.7 mg/dL) reduction in LDL-C reduces major cardiovascular events by approximately 22% (CTT Collaboration meta-analysis). Elevated LDL-C is the primary modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD): coronary artery disease, ischaemic stroke, and peripheral arterial disease. Statin therapy is the cornerstone of LDL-C lowering; additional agents include ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab), and inclisiran. Familial hypercholesterolaemia (FH — LDL-C typically >190 mg/dL) requires early, aggressive treatment. Non-HDL cholesterol (Total − HDL) is an alternative target when triglycerides are elevated.